Direct Oral Anticoagulant Monotherapy Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: A Meta-Analysis of Randomized Trials

Figures

• 

  Figure.. Short-term outcomes with direct oral anticoagulant (DOAC) vs dual antiplatelet therapy (DAPT) after left atrial appendage closure (LAAC). The left illustrates the contribution of each randomized trial, the pooled sample size with 60 to 90-day follow-up, key trial-level design features, and baseline clinical and procedural characteristics of the included patients. The right illustrates pooled RRs with 95% CIs, P values, and I2 estimates between DOAC monotherapy and DAPT for the prespecified outcomes. ACD indicates all-cause death; ADALA, Apixaban Versus Dual Antiplatelet Therapy Study After Left Atrial Appendage Occlusion; ADRIFT, Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure; ANDES, Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure; ASA, acetylsalicylic acid; BARC, Bleeding Academic Research Consortium; BR, bleeding risk; DRT, device-related thrombosis; eGFR, estimated glomerular filtration rate; HBR, high bleeding risk; HD, hemostasis disorder; Het., heterogeneity; I2, inconsistency index; INR, labile international…